

**Key Constraints for ALLERGY Service Provision**

Note much of allergy is specialist commissioned



- Staffing – medical, nursing, allied health, administrative
- Outpatient facilities with sufficient social distancing – requirement for some face-to-face visits; need for *in vivo* testing (eg skin prick and intradermal testing)
- Day-case facilities with sufficient social distancing – requirement for day-case procedures (eg food/drug challenges, drug desensitisation, venom/aeroallergen immunotherapy, home-therapy training)

**Priorities**

**At 25% staffing/facilities capacity the following activity would be prioritised.**

This assumes that patients will be reviewed by telephone clinics only, with subsequent face-to-face visit for testing where needed. Assumes very limited if any day-case facility availability.

Outpatient assessment:	Procedures:
<ul style="list-style-type: none"> <li>- Drug allergy when urgently required and alternatives unacceptable* Including general/local anaesthetic allergy and chemotherapy/biologics*</li> <li>- Food allergy assessment where there is nutritional concern*</li> <li>- Angioedema with low complement C4</li> <li>- Likely systemic mastocytosis with B or C findings</li> <li>- Severe anaphylaxis</li> </ul>	<ul style="list-style-type: none"> <li>- Facilitation of rapid drug desensitisation if possible when required</li> <li>- Food and drug challenges only in exceptional circumstances</li> <li>- Stop all immunotherapy (IT) up-dosing and restart when capacity resumes</li> <li>- Maintenance venom IT only if high benefit and low vulnerability</li> </ul>

**At 50% staffing/facilities capacity, in addition to the activities above the following activity would be prioritised.**

This assumes that patients will be reviewed face-to-face if testing is required, with the majority being telephone clinics. Assumes some day-case facility availability.

Outpatient assessment:	Procedures:
<ul style="list-style-type: none"> <li>- Drug allergy if alternatives available but therapeutically inferior*</li> <li>- Food allergy where there is limited diet*</li> <li>- Idiopathic anaphylaxis</li> <li>- Severe spontaneous urticaria and angioedema (for biologic therapy)</li> <li>- NSAID-exacerbated respiratory disease</li> <li>- Occupational allergy*</li> <li>- Venom allergy*</li> <li>- Severe asthma/eczema*</li> </ul>	<ul style="list-style-type: none"> <li>- Food and drug challenges if essential</li> <li>- Omalizumab home therapy training</li> <li>- Initiation of venom IT</li> <li>- Maintenance venom immunotherapy (IT)</li> <li>- Initiation of sublingual immunotherapy (SLIT)</li> </ul>

**At 75% staffing/facilities capacity, in addition to the activities above the following activity would be prioritised**

This assumes that patients will be reviewed face-to-face if testing is required, with the majority being telephone clinics. Assumes regular day-case facility availability.

Outpatient assessment:	Procedures:
<ul style="list-style-type: none"> <li>- Anaphylaxis with simple trigger and cofactors (eg asthma)*</li> <li>- Drug allergy with likely future need*</li> <li>- Non-immediate GI food allergy (eg eosinophilic oesophagitis)</li> <li>- Moderately controlled spontaneous urticaria and angioedema</li> <li>- Chronic rhinosinusitis with asthma*</li> </ul>	<ul style="list-style-type: none"> <li>- Food and drug challenges</li> <li>- Maintenance aeroallergen subcutaneous IT</li> <li>- In-hospital omalizumab dosing</li> </ul>

**At 90% staffing/facilities capacity, in addition to the activities above the following activity would be prioritised**

This assumes that patients will be reviewed face-to-face if needed, with the remainder being telephone clinics. Assumes dedicated day-case facility availability.

Outpatient assessment:	Procedures:
<ul style="list-style-type: none"> <li>- First presentation anaphylaxis*</li> <li>- Spontaneous urticaria and angioedema</li> <li>- General food allergy*</li> <li>- General drug allergy*</li> <li>- Chronic rhinosinusitis*</li> </ul>	<ul style="list-style-type: none"> <li>- Initiation of aeroallergen subcutaneous IT</li> </ul>

\*probably requires at least one face-to-face visit for skin testing or other investigation